CRISPR Therapeutics AG
HealthcareNASDAQ:CRSP · NASDAQ Global Market
-$0.43 today
Vol 1.15M · Avg 1.75M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-30.3%
avg -8.2%
ROIC
-26.6%
avg -17.2%
ROA
-25.7%
avg -14.4%
Analysis
ROA is currently the strongest return metric at -25.7% versus its period average of -14.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Samarth Kulkarni | Chief Executive Officer & Chairman | $1.43M | — | 48 | $255,501.00 | 0.26% |
Naimish Patel | Chief Medical Officer | $858,490.00 | — | 54 | $19,357.00 | 0.02% |
James R. Kasinger | General Counsel & Secretary | $780,577.00 | — | 54 | $17,000.00 | 0.02% |
Raju Yashaswi Prasad | Chief Financial Officer | $779,557.00 | — | 42 | $19,500.00 | 0.02% |
Shaun Foy | Co-Founder | — | — | — | — | — |
Chad A. Cowan | Scientific Founder | — | — | 54 | — | — |
Craig C. Mello | Co-Founder & Scientific Advisory Board Member | — | — | — | — | — |
Daniel G. Anderson | Co-Founder & Scientific Advisory Board Member | — | — | 56 | — | — |
Emmanuelle Marie Charpentier | Co-Founder & Scientific Advisory Board Member | — | — | — | — | — |
Matthew Porteus | Co-Founder & Scientific Advisory Board Member | — | — | 61 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$52.64M
Sells
27
$17.63M
Net Sentiment
+$35.01M
Net buying
Most Active
Prasad Raju
10 transactions
1–10 of 31
Analysis
Insiders reported 4 buys worth $52.64M and 27 sells worth $17.63M over the last 12 months. That adds up to net buying of $35.01M. Prasad Raju was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +133.0% | +86.4% (12yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +133.0% over three years. Forward estimates point to Revenue at +86.4% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.37B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Cytokinetics, Incorporated
NASDAQ:CYTK
$8.73B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Metsera, Inc.
MTSR
$7.43B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.85B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
Akero Therapeutics, Inc.
AKRO
$4.50B
Who manages CRSP?
CRISPR Therapeutics AG (CRSP) lists 10 active executives. The top listed executive is Naimish Patel, Chief Medical Officer.
Are CRSP insiders buying or selling?
Recent insider activity shows net buying of $75.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.